Market closed

scPharmaceuticals/$SCPH

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About scPharmaceuticals

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Ticker

$SCPH

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Burlington, United States

Employees

136

Website

www.scpharmaceuticals.com

SCPH Metrics

BasicAdvanced

$176M

-

-$1.96

0.10 -

Price and volume

Market cap

$176M

Beta

0.1

52-week high

$6.54

52-week low

$3.08

Average daily volume

451K

Financial strength

Current ratio

8.08

Quick ratio

6.672

Long term debt to equity

170.198

Total debt to equity

170.95

Interest coverage (TTM)

-7.79%

Management effectiveness

Return on assets (TTM)

-34.44%

Return on equity (TTM)

-200.65%

Valuation

Price to revenue (TTM)

4.734

Price to book

5.72

Price to tangible book (TTM)

5.72

Price to free cash flow (TTM)

-2.031

Growth

Revenue change (TTM)

303.87%

Earnings per share change (TTM)

43.06%

3-year earnings per share growth (CAGR)

23.38%

What the Analysts think about SCPH

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for scPharmaceuticals stock.

SCPH Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

SCPH Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

SCPH News

AllArticlesVideos

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

GlobeNewsWire·5 days ago

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SCPH

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for scPharmaceuticals stock?

scPharmaceuticals (SCPH) has a market cap of $176M as of January 15, 2025.

What is the P/E ratio for scPharmaceuticals stock?

The price to earnings (P/E) ratio for scPharmaceuticals (SCPH) stock is 0 as of January 15, 2025.

Does scPharmaceuticals stock pay dividends?

No, scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next scPharmaceuticals dividend payment date?

scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders.

What is the beta indicator for scPharmaceuticals?

scPharmaceuticals (SCPH) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.